Trading & Business Update

Cambridge Nutritional Sciences plc (AIM:CNSL) has released a trading and business update, projecting total revenue of £7.0 million for the year ending March 31, 2026, down from £8.3 million in the previous year. This decline is attributed primarily to geopolitical instability affecting orders from the Middle East and Asia. However, the company reports an underlying revenue growth of approximately 11% when excluding these regions. Despite the revenue challenges, Cambridge Nutritional Sciences has maintained a robust gross profit margin of 67.8%, an increase from 65.3% in 2025, and anticipates an adjusted EBITDA loss of £0.4 million, a reversal from a profit of £0.4 million in the prior year. The company also disclosed a net cash balance of £2.6 million, down from £4.9 million in the previous year.

This announcement reveals a mixed picture for Cambridge Nutritional Sciences. While the projected revenue decline is concerning, the underlying growth of 11% suggests that the company's core operations are performing well, particularly in the UK and Indian markets. The CEO, James Cooper, expressed satisfaction with the underlying revenue growth, emphasizing the company's focus on manufacturing efficiencies that have driven the gross margin increase. However, the anticipated EBITDA loss raises questions about the company's ability to manage costs effectively in light of declining revenues. The significant drop in net cash also indicates a potential funding challenge, especially as the company navigates a disrupted trading environment.

When contextualizing this announcement against prior disclosures, it is evident that Cambridge Nutritional Sciences is facing challenges that were not fully anticipated in previous communications. The company had previously reported a profit of £0.4 million for the year ending March 2025, and the shift to an EBITDA loss highlights a deterioration in financial performance. Furthermore, while the company cites geopolitical instability as a primary factor for the revenue decline, it is crucial to assess whether this situation was adequately communicated to investors in earlier updates. The current announcement suggests that the company may have underestimated the impact of external factors on its operations.

In terms of financial position, the company's net cash balance of £2.6 million is a critical metric to consider. This figure represents a significant decrease from the previous year's balance of £4.9 million and raises concerns about the company's funding runway. Given the anticipated EBITDA loss of £0.4 million, the current cash position may not be sufficient to support ongoing operations without additional financing. Investors should be cautious about the potential for dilution if the company needs to raise capital to sustain its operations.

Valuation comparisons with peers in the medical diagnostics sector reveal that Cambridge Nutritional Sciences is operating in a challenging environment. The company currently has a market capitalization of approximately GBP 4.6 million. In comparison, peers such as Abcam plc (LSE:ABC) and Oxford Biomedica plc (LSE:OXB) have market capitalizations of GBP 2.5 billion and GBP 1.1 billion, respectively. While these companies are significantly larger, they also provide a benchmark for evaluating Cambridge Nutritional Sciences' performance. The gross profit margin of 67.8% is competitive, but the anticipated EBITDA loss indicates that the company is struggling to translate revenue into profit, a critical metric that investors will scrutinize.

The execution record of Cambridge Nutritional Sciences is another area of concern. The company has highlighted its continued progress in its In Vitro Diagnostic Regulation (IVDR) development program, which is expected to yield significant advantages in product, cost, and market position. However, the lack of specific timelines or milestones related to this program raises questions about the company's ability to deliver on its strategic objectives. Investors will be looking for concrete updates on this front in the upcoming audited results scheduled for July 2026.

One specific red flag arising from this announcement is the anticipated EBITDA loss of £0.4 million, which contrasts sharply with the previous year's profit. This shift suggests that the company may be facing operational inefficiencies or challenges in cost management, particularly in light of the revenue decline. Additionally, the significant drop in net cash raises concerns about the company's financial health and its ability to navigate ongoing geopolitical uncertainties.

Looking ahead, the next expected catalyst for Cambridge Nutritional Sciences is the release of its audited final results in July 2026. This report will provide further insights into the company's financial performance and operational developments, which will be critical for investors assessing the company's trajectory.

In conclusion, the trading and business update from Cambridge Nutritional Sciences can be classified as moderate. While the underlying revenue growth of 11% is a positive indicator, the projected decline in total revenue, the anticipated EBITDA loss, and the significant drop in net cash present a concerning picture. The headline sentiment may appear positive at first glance, but a deeper analysis reveals substantial challenges that the company must address to reassure investors and stabilize its financial position. Investors should remain cautious and await further updates in July 2026 to gauge the company's ability to navigate these challenges effectively.

Key insights

• ●CNSL expects £7.0m revenue, down from £8.3m, primarily due to geopolitical instability.
• ●Anticipated EBITDA loss of £0.4m contrasts sharply with £0.4m profit in 2025.
• ●Net cash balance has dropped to £2.6m, raising concerns about funding sufficiency.

Disagree with this article?